DUBLIN – Numab Therapeutics AG could earn up to CHF258 million (US$262 million) in up-front and milestone payments from a research and option agreement with Ono Pharmaceutical Co. Ltd., in which it will deploy its multispecific antibody fragment technology in the search for a molecule that simultaneously binds a novel immuno-oncology target nominated by Ono as well as other complementary targets.